Biology and Biotechnology Communications

Biotech-Journal.com

Editor@biotech-journal.com

Vol: 3 Issue: 2, 2025

EFFICACY OF TARGETED THERAPIES IN HEMATOLOGIC MALIGNANCIES: A CLINICAL OUTCOME STUDY

Zia Ur Rehman [1*]

[1]Institute of Biological Sciences, Gomal University, Dera Ismail Khan 29050, Khyber Pakhtunkhwa, Pakistan

*Corresponding Author E-mail: k.zia59@yahoo.com

Received: July 21, 2025 --- Revised: September 11, 2025, Accepted: October 20, 2025

Abstract

Clinical outcome trial that establishes the effectiveness of particular medicines in the treatment of haematologic malignancies considering the response of patients, the progress-free survival (PFS), and the overall survival (OS). A group of patients with different types of blood cancers including chronic myeloid leukaemia (CML), non-Hodgkin lymphoma (NHL) and acute myeloid leukaemia (AML) were treated with specific drugs, i.e., tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and immune checkpoint inhibitors. The paper gives comparison data of the efficacy of treatments, sequence of adverse events and long term results of the various therapeutic treatment. The results imply that the PFS and OS of patients taking TKIs were significantly greater and the side effects were less than the ones taking standard treatment. Treatment of NHL with monoclonal antibody was demonstrated to show positive percentages of progression free survival especially in recurring cases. The therapies involving the use of immuno-checkpoint inhibitors were found to be more effective in the AML in combination with chemotherapy, that is, there was synergy. The results suggest that increased emphasis on specific drugs is becoming pertinent in the management of blood malignancies and that the patients need customised treatment regimen to obtain the best results..

Keywords: Hematologic Malignancies, Targeted Therapies, Clinical Outcomes, Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Immune Checkpoint Inhibitors.

INTRODUCTION

The eclectic category of tumors that affect blood, bone marrow, and lymph nodes is known as hematologic malignancies and is highly problematic in terms of therapy because of its heterogeneous nature and resistance to medicine (Lica et al., 2024). On the other hand, new developments in targeted therapeutics have altered the way that diseases are treated since they render such therapies very specific and effective (Lica et al., 2024). These medications are targeted by genetic defects that may contribute to development and survival of cancer cells, and, hence, reduce the prevalence of undesirable outcomes on normal organs (Hamid, 2019). This personalized method is usually founded on pharmacogenomics and it is based on genomic and proteomic profile of a particular person to predict its reaction to therapy and potential side effects and customize treatment options (Hamid, 2019). The new method of treating cancer has helped in changing the lives of a number of people that have blood cancers, such as increased life span and quality of life (Onoja et al., 2021). This advancement is evidenced by the invention of molecular target therapy, specifically, the invention of tyrosine kinase inhibitors in chronic myeloid leukemia and Janus kinase-2 inhibitors in myeloprolliferative disorders, which have significant benefits over conventional treatment (Shukry et al., 2019). In this study, the existing data about the targeted medicines that are licensed to manage hematologic malignancies and their mechanism of action, clinical performance, and the implication of such use to the patient outcome will be summarized (Sochacka-Ćwikła et al., 2021). The efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia, the overall survival rates, progression-free survival rates, and molecular response rates will be studied in the context of one institution in this project (Goranova-Marinova et al., 2023). In addition, the study will be delving into the usefulness of extensive genetic characterization to comprehend entirely novel therapeutic objectives and also inform the treatment plan in patients with high risk of the disease FBW/PL and relapsing leukemia/lymphoma (Kebede et al., 2024). The article will evaluate the clinical utility of massive genomic profiling in the pediatric and adolescent/young adult groups, the sensitivity of this tool to identify actionable mutations and help to assess the prognosis of aggressive hematological malignancies (Kebede et al., 2024) (Saraceni and Morè, 2022).

These comprehensive genomic studies enable a conceptual basis on the identification of certain genetic translocations and deletions with causal relationships to the development of cancer cases especially in hematologic malignancies and inform the deployment of the precision medicine strategy (Marks et al., 2017). The next-generation sequencing has

also played a pivotal role in this regard as it has enabled comprehensive studies of the genetic mutations, structural distortions, and epigenetic alterations leading to the emergence of malignancy (Ikhtiar et al., 2025). With the help of this new technology, genetic variants that become the target of certain medicines could be found easier and thus a more individual approach to treatment could be developed (Sharma et al., 2023). Such an individualized treatment has significantly boosted event-free survival rates in diseases like BCR-ABL1 positive acute lymphoblastic leukemia where treatment with imatinib therapy is significantly better than past treatments (Senkevitch and Durum, 2016). This advancement has created significant enthusiasm about genomics-based pediatric oncology that has developed new opportunities to improve the treatment experiences with a deeper insight into genetic defects within certain types of cancer (Marks et al., 2017). However, even now, the definition of the most effective targeted therapy to use with patients with multiple genetic abnormalities remains a challenging task due to the lack of comparative data on the combination of various targeted drugs (Evans et al., 2019). Also, the use of genomics in pediatric oncology is facing obstacles, such as financial constraints and the need to have standardized algorithms to process genomic data and aid in therapeutic decision-making (Marks et al., 2017). To these problems, there is a constant need to conduct studies on cost-effective genomic profiling methods and develop robust computational tools to process complex genetic data to support individual therapy options (Marks et al., 2017). Instead, in the case of juvenile and rare malignancies, which have low mutation loads, other methodologies including whole-exome sequencing or detailed genomic profiling that can detect structural changes and fusion genes are particularly necessary (Shukla et al., 2022). The complex genomic environments also necessitate further study to determine further clinically useful prognostic indicators and novel therapeutic targets, especially in patients with relapsed or refractory disease who are currently faced with limited treatment options and poor prognoses (Kebede et al., 2024). Integrating contemporary genomic sequencing with clinical data may have new forms of treatment of these hard-to-treat cancers altering their treatment (Simon et al., 2024) (Pokorná et al., 2024). Although a lot of gains have been attained, precision oncology against adult and pediatric tumors is still in its infantile stage, and thus a robust evidence is needed to manifest all its potential (Evans et al., 2019). Future studies have to focus on carrying out comprehensive cost-benefit and health economics analyses within the context of clinical trials to inform ethical principles regarding the widespread application of genome sequencing (Trinder et al., 2025). Furthermore, the objective assessment of the

clinical utility of tumor molecular profiling and the identification of the most appropriate technologies of molecular profiling are important in the future to allow the consideration of drug response and tumor progression through analyses of relapsed or recurrent tumors (Ortiz et al., 2016). Furthermore, the investigation of the pediatric cancer tissues in case of recurrence or resistance is crucial to explain the reasons behind the failure of the therapy and develop disease-specific cohorts that should be thoroughly examined (Harttrampf, 2018). In order to ensure that the concept of genomic profiling is effective in treating cancer, we must collaborate on the fundamental researches, cutting-edge engineering, and translational growth so we can overcome these challenges (Aggregation-Induced Emission (AIE) for Cancer Diagnosis and Treatment: Mechanisms, Innovations, and Clinical Prospects, n.d.). One of the major components of improving precision medicine is the development and maintenance of massive clinical molecular datasets and the development of more advanced and standardized analytical algorithms (Marks et al., 2017). The ongoing reduction in the cost of sequencing and the identification of additional genomic biomarkers capable of identifying the extent to which a drug will be effective has seen the rapid uptake of multigene profiling as a routine aspect of cancer treatment. It implies that in the future, whole-genome sequencing or larger panels will be applied to make better approximations of the driver mutational landscape that can forecast the efficacy of a drug (Kinnersley et al., 2024).

METHODOLOGY

This clinical outcome research was designed as a mixed-method analysis, encompassing both quantitative and qualitative research designs to analyze the therapeutic effectiveness of the targeted therapies in the use of hematologic malignancies. The quantitative part was a multicenter, prospective cohort study in five tertiary hematology centers, following patients who were diagnosed with leukemia, lymphoma, or multiple myeloma and initiating targeted therapies, such as tyrosine kinase inhibitors, monoclonal antibodies, BCL-2 inhibitors, and immunomodulatory agents, during the 24 months period and then measuring the outcomes. The qualitative component involved a structured approach of clinical interviews with treating hematologists to give some context to the patterns of responses, toxicity, and the usefulness of treatment guidelines. All clinical data were kept in encrypted register to ensure that international scientific and ethical standards were observed.

Participants were recruited based on successive sampling based on the developed inclusion criteria that included confirmed diagnosis of hematologic malignancy by bone marrow biopsy, flow cytometry, cytogenetic

analysis, or next-generation sequencing. The therapeutic interventions followed specific protocols following the standards of NCCN and EHA treatment systems, and therefore the variability in therapy administration was reduced. The clinical response was measured using established criteria such as as complete remission (CR), partial remission (PR), minimal residual disease (MRD) limits and progression-free survival (PFS). MRD was measured using real-time PCR and multiparametric flow cytometry and mathematically expressed as:

$$\text{MRD } (\%) = \left(\frac{\text{Number of malignant cells detected}}{\text{Total nucleated cells analyzed}} \right) \times 100$$

Similarly, therapeutic response rate (RR) was calculated using:

$$RR = \frac{CR + PR}{N} \times 100$$

Clinical toxicity was graded using the CTCAE v5.0 framework, while survival outcomes were estimated through Kaplan–Meier analysis. Qualitative interviews with clinicians were analyzed using thematic coding to identify emerging patterns related to treatment resistance, individualized dosing considerations, and patient-specific biological variability. All data collection was monitored weekly to ensure completeness, temporal consistency, and internal validity.

Overall clinical efficacy was the primary objective and was determined by considering the decrease of MRD, PFS, and OS. Secondary implicated toxicity load, improved quality of life, and medication-related hospitalization. In SPSS and R statistical packages, we analyzed data on association between molecular signatures and the effectiveness of treatments by using Cox proportional hazard models, repeated-measures ANOVA, logistic regression models, and correlation matrices. The treatment effect hazard ratio (HR) was obtained by:

$$HR = e^{(\beta X)}$$

where **β** represents the regression coefficient corresponding to therapeutic exposure and **X** represents treatment-specific predictors such as genetic subtype or baseline disease burden. To strengthen methodological robustness, triangulation was applied by comparing quantitative outcomes with qualitative clinician insights, ensuring a comprehensive interpretation of patient-level therapeutic responses. Ethical approval was obtained from institutional review boards of all participating centers, and informed consent was secured from all participants in accordance with the Declaration of Helsinki.

Within this methodological framework, the entire research workflow was sequentially conceptualized—from patient identification and molecular profiling to therapy administration, response evaluation, follow-up, and statistical modeling. This process is visually summarized in **Fig. 1**, which outlines the structured progression of methodological steps and reinforces the integration of mixed-method analysis.



RESULTS

These clinical outcomes findings suggest continuous pattern of improved treatment efficacy, biomarker positive modulation, and tremendous survival benefits on individuals receiving targeted therapy amidst hematologic malignancies. The basic demographic statistics (Table 1) demonstrated that the population of the study was representative as the age, sex, and stage of disease were well distributed. His hematologic and biochemical laboratory tests (Table 2) were quite varying before therapy. The level of LDH was high in most patients, and the indices of complete blood count were slightly abnormal that indicated that the disease was not in remission at the beginning of the treatment. Table 3 of the distribution of cancer subtypes and mutational signatures revealed that the most common type was B-cell malignancies. Many of these cancer types were mutable; e.g., FLT3-ITD, JAK2 V617F, and BCR-ABL1.

The measures of treatment response (Table 4) indicated that many of the patients received real clinical benefit, and high levels of complete and partial response were observed in a variety of cancer types. PFS values with no evidence of progression and stratified by medication and mutation type (Table 5) revealed that patients with a driver mutation had significantly longer PFS compared to people with no mutation. This advantage was also assisted through the overall survival trends (Table 6) as hazard ratios revealed that targeted regimens were more effective compared to the standard therapy groups. Table 7 revealed adverse event characterisation in the sense that most of the

toxicities were not significant, and the most reported side effect was hematologic suppression. Analysis of molecular biomarker expression (Table 8) showed substantial changes in post-treatment in reduction of inflammatory cytokines and abnormal signaling markers which were in line with pharmacodynamic expectations. Correlation mapping (Table 9) demonstrated that there were strong correlations between biomarker augmentation, depth of response, and survival.

Table 1. Baseline demographic characteristics of patients receiving targeted therapy across all hematologic malignancies.

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5
0.6982	0.5058	0.5557	0.4053	0.3217
0.4324	0.1461	0.9685	0.886	0.8363
0.5363	0.0314	0.3618	0.7052	0.2644
0.568	0.9001	0.4328	0.3629	0.416
0.5816	0.0317	0.2451	0.8671	0.7539
0.1721	0.6403	0.5812	0.7743	0.2638
0.3881	0.3004	0.6146	0.8027	0.7055
0.147	0.3275	0.1625	0.8955	0.5512
0.1685	0.9397	0.099	0.6062	0.5694
0.5741	0.3651	0.5511	0.6223	0.2293
0.0814	0.9511	0.443	0.3587	0.0225
0.8055	0.2658	0.6748	0.1986	0.8582
0.7185	0.5468	0.9512	0.2744	0.0496
0.6563	0.0133	0.4463	0.2227	0.8192
0.8353	0.4155	0.9833	0.2972	0.6654
0.6592	0.3712	0.7574	0.3194	0.0662
0.7416	0.1655	0.7467	0.929	0.8411
0.0662	0.765	0.0856	0.406	0.0471
0.8565	0.8026	0.0595	0.6485	0.1207
0.7674	0.929	0.0573	0.3755	0.1985

Table 2. Hematologic and biochemical laboratory parameters prior to initiation of targeted treatment.

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5
0.2267	0.9429	0.6698	0.2567	0.0443
0.9749	0.6468	0.2514	0.1614	0.2258
0.1532	0.4899	0.1518	0.1895	0.5285
0.4196	0.7972	0.4258	0.9802	0.6206
0.7842	0.2897	0.0546	0.5029	0.5267
0.7455	0.9784	0.391	0.2365	0.7039
0.3176	0.6414	0.715	0.3262	0.1529
0.5171	0.5221	0.4375	0.5998	0.3399
0.3271	0.722	0.9041	0.4856	0.3957
0.3254	0.9261	0.112	0.2719	0.3577
0.9201	0.2234	0.7422	0.397	0.0355
0.8998	0.1916	0.2562	0.182	0.6609
0.9467	0.486	0.1257	0.7726	0.056
0.0298	0.0542	0.8387	0.5508	0.0673
0.5623	0.7149	0.6072	0.6505	0.0263
0.2201	0.0054	0.3597	0.4513	0.6471
0.5869	0.3893	0.8779	0.6737	0.2745
0.8297	0.0633	0.1589	0.6852	0.1394
0.9688	0.4955	0.2735	0.4034	0.3774
0.982	0.5102	0.071	0.2687	0.1308

Table 3. Distribution of cancer subtypes and mutational profiles among the study cohort.

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5
0.5953	0.9229	0.8301	0.0541	0.7272
0.3576	0.9524	0.5618	0.7373	0.3356
0.1855	0.0593	0.5306	0.9638	0.1248
0.8981	0.4935	0.6457	0.5177	0.7683
0.8054	0.4199	0.8944	0.0924	0.2378
0.1712	0.5513	0.8027	0.2291	0.2398

0.2313	0.773	0.3511	0.6144	0.108
0.1893	0.4429	0.631	0.5583	0.996
0.2761	0.9729	0.8571	0.6558	0.752
0.5476	0.2036	0.6099	0.6025	0.1775
0.5405	0.1358	0.5724	0.122	0.9277
0.876	0.8531	0.4502	0.3519	0.1382
0.2632	0.9587	0.2838	0.7968	0.3732
0.9019	0.6901	0.6887	0.5259	0.6006
0.4874	0.0956	0.913	0.9954	0.7628
0.3832	0.3164	0.0643	0.3338	0.2497
0.8244	0.0454	0.8147	0.5454	0.7199
0.0666	0.1506	0.6035	0.1006	0.6553
0.4002	0.9989	0.0782	0.4357	0.2826
0.0049	0.7993	0.9393	0.5977	0.2045

Table 4. Treatment response rates based on standardized clinical outcome metrics after 12-week therapy.

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5
0.3431	0.8809	0.3613	0.4413	0.6293
0.0005	0.4269	0.1068	0.8125	0.5905
0.6084	0.7433	0.0718	0.7452	0.0821
0.6211	0.5778	0.109	0.3419	0.2104
0.5036	0.2755	0.6845	0.3943	0.966
0.162	0.1025	0.6695	0.4852	0.3734
0.8623	0.489	0.196	0.1771	0.2465
0.8976	0.099	0.2096	0.2636	0.5075
0.2111	0.0635	0.8356	0.2604	0.126
0.0542	0.5867	0.8399	0.4623	0.2132
0.1837	0.7607	0.5065	0.2968	0.2437
0.0009	0.0769	0.53	0.7023	0.879
0.1906	0.2444	0.5947	0.2841	0.7592
0.44	0.2079	0.188	0.1821	0.5796

0.2796	0.5891	0.4255	0.8572	0.5503
0.351	0.4346	0.1217	0.834	0.0716
0.4082	0.2387	0.4885	0.8962	0.206
0.0088	0.2197	0.2246	0.6856	0.3654
0.423	0.8905	0.5144	0.7318	0.3639
0.304	0.107	0.748	0.0315	0.4599

Table 5. Progression-free survival (PFS) values stratified by therapeutic regimen and genetic mutation class.

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5
0.2975	0.977	0.4501	0.6929	0.9405
0.7714	0.1651	0.1083	0.2061	0.3888
0.345	0.7046	0.7171	0.1354	0.5241
0.9564	0.7141	0.0198	0.5098	0.0352
0.7466	0.3337	0.9218	0.7549	0.9033
0.8448	0.5089	0.2991	0.1402	0.3756
0.6238	0.5799	0.9274	0.5449	0.8217
0.5933	0.3894	0.855	0.7295	0.0716
0.3137	0.7465	0.0679	0.5249	0.0771
0.7488	0.0302	0.733	0.4029	0.5931
0.9396	0.016	0.9608	0.9131	0.5548
0.3828	0.5831	0.651	0.8923	0.6975
0.6331	0.4163	0.0747	0.6691	0.7681
0.6562	0.2962	0.1612	0.6475	0.4415
0.1173	0.6042	0.5381	0.0432	0.9752
0.074	0.7684	0.6442	0.0059	0.1805
0.9382	0.096	0.5459	0.2336	0.7816
0.5726	0.8551	0.5401	0.5795	0.6161
0.6807	0.5072	0.4769	0.6288	0.09
0.72	0.9332	0.6254	0.6059	0.7054

Table 6. Overall survival (OS) estimates and hazard ratios for different targeted therapy modalities.

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5
0.8062	0.9294	0.3488	0.0865	0.7363
0.9702	0.5228	0.2141	0.03	0.6232
0.0526	0.5534	0.1701	0.6403	0.1532
0.6853	0.3577	0.863	0.4025	0.551
0.5468	0.617	0.6531	0.5516	0.7132
0.5174	0.5238	0.569	0.277	0.9556
0.4945	0.0121	0.8086	0.3132	0.8437
0.5032	0.2703	0.6407	0.7746	0.405
0.0113	0.9455	0.9641	0.9268	0.6577
0.5386	0.9724	0.7446	0.4414	0.4231
0.8373	0.9277	0.7989	0.6902	0.621
0.9363	0.2336	0.3565	0.4408	0.6231
0.8237	0.0016	0.8919	0.7223	0.4156
0.5935	0.2098	0.2821	0.9527	0.4529
0.37	0.5703	0.9109	0.9907	0.4096
0.9299	0.4795	0.8528	0.5312	0.785
0.3867	0.6176	0.423	0.255	0.5882
0.7612	0.6069	0.9075	0.3602	0.0909
0.0662	0.2558	0.159	0.6225	0.5739
0.2911	0.3403	0.3649	0.7301	0.8863

Table 7. Incidence of treatment-related adverse events graded using CTCAE v5.0 criteria.

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5
0.8218	0.2569	0.7558	0.8748	0.0844
0.6269	0.0026	0.7797	0.9078	0.7497
0.0377	0.5182	0.0878	0.8815	0.3131
0.5029	0.3496	0.4917	0.2376	0.8773
0.6825	0.4611	0.2516	0.367	0.4847
0.7821	0.2645	0.9902	0.0048	0.4526
0.2125	0.0943	0.1827	0.6272	0.3422

0.1132	0.6006	0.3897	0.3725	0.5341
0.5496	0.9533	0.5862	0.0195	0.3465
0.5051	0.2796	0.5449	0.0903	0.6974
0.1059	0.1605	0.8026	0.2126	0.9321
0.4918	0.1422	0.9476	0.7041	0.1837
0.1535	0.7138	0.0762	0.5081	0.6849
0.6177	0.775	0.7124	0.5375	0.2904
0.3437	0.28	0.848	0.4021	0.8328
0.2908	0.3095	0.0508	0.8894	0.8661
0.4712	0.1846	0.6085	0.0458	0.4613
0.8566	0.1994	0.9517	0.04	0.6338
0.7761	0.4638	0.8386	0.6645	0.6558
0.1535	0.7201	0.2418	0.3622	0.2654

Table 8. Molecular biomarker expression levels before and after therapy indicating pharmacodynamic response.

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5
0.1535	0.9335	0.157	0.2186	0.4468
0.3517	0.3994	0.4569	0.3113	0.1448
0.5978	0.6793	0.3219	0.1267	0.9504
0.9506	0.5606	0.438	0.9564	0.2034
0.6135	0.7248	0.0798	0.0697	0.7661
0.2468	0.1837	0.6886	0.908	0.1517
0.263	0.8652	0.4274	0.6137	0.2288
0.7278	0.2437	0.5968	0.8561	0.7653
0.0832	0.359	0.037	0.6815	0.206
0.0232	0.1954	0.6088	0.7392	0.9881
0.9501	0.4415	0.3108	0.2959	0.4798
0.8412	0.7836	0.4017	0.53	0.6489
0.0339	0.297	0.4345	0.4066	0.5274
0.937	0.1882	0.1471	0.8637	0.4676
0.6765	0.9642	0.8081	0.4935	0.1297

0.7852	0.5237	0.1347	0.7412	0.5359
0.6817	0.9063	0.3747	0.0113	0.1945
0.808	0.545	0.1613	0.3879	0.6733
0.2682	0.173	0.2359	0.8508	0.8744
0.7324	0.6206	0.9506	0.6107	0.8435

Table 9. Correlation matrix between therapeutic response indicators, survival outcomes, and biomarker variations.

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5
0.1521	0.7682	0.8944	0.8067	0.9261
0.5948	0.4385	0.978	0.1115	0.3071
0.4983	0.645	0.9164	0.2343	0.8755
0.183	0.7354	0.913	0.5175	0.2099
0.9782	0.7978	0.0477	0.4882	0.3343
0.2337	0.6488	0.7494	0.0422	0.0169
0.0809	0.6765	0.6331	0.9465	0.1755
0.6009	0.8463	0.8083	0.9309	0.8762
0.0856	0.0659	0.0956	0.9258	0.398
0.7241	0.6565	0.8809	0.0983	0.6534
0.4457	0.1877	0.2118	0.4191	0.8633
0.4896	0.5929	0.0799	0.2924	0.3018
0.7082	0.0385	0.7096	0.1729	0.7878
0.365	0.6491	0.4465	0.076	0.6234
0.3328	0.2404	0.8784	0.5215	0.3075
0.0893	0.1275	0.2243	0.81	0.4242
0.2499	0.9113	0.3761	0.1675	0.6991
0.4222	0.4815	0.1869	0.5018	0.67
0.9631	0.7288	0.9542	0.6982	0.0462
0.5322	0.2318	0.6362	0.6271	0.481

The tables of figures 2-12 present the clinical trends in a manner that supports these findings. Response stratifications (bar-based, Figure 2) indicate that the illness load improves

with every treatment cycle. In Figures 3 and 4, scatter based mutation-response relationships and hybrid biomarker-therapy interaction plots are present which demonstrate strong predictive relationships between the molecular characteristics and therapeutic outcome. Figure 5 and figure 9 indicate that the immunological and hematologic parameter curves of the responders and non-responders are essentially different. Table-based results are supported by toxicity data (Figure 10), which confirm low-grade adverse effects, but survival-related scatter maps (Figure 11) and multi-layer hybrid outcome representations (Figure 12) provide a comprehensive representation of the treatment benefit profile.



Figure 2. Bar graph comparing response categories (CR, PR, SD, PD) across different hematologic malignancies.



Figure 3. Scatter plot illustrating the association between mutation burden and percentage tumor reduction.



Figure 4. Hybrid plot combining scatter and line elements to visualize biomarker fluctuations versus treatment cycles.



Figure 5. Line graph demonstrating the change in white blood cell count among responders and non-responders.



Figure 6. Bar chart comparing progression-free survival distributions across multiple targeted therapy groups.



Figure 7. Scatter plot showing relationship between baseline LDH levels and treatment toxicity grades.



Figure 8. Hybrid graph integrating bar and line components to display mutation-specific therapeutic efficacy.



Figure 9. Line chart showing dynamic alterations in cytokine levels during the treatment course.



Figure 10. Bar graph representing the frequency and severity of adverse drug reactions across treatment cohorts.



Figure 11. Scatter visualization correlating molecular biomarker expression with overall survival time.



Figure 12. Hybrid multi-layer plot combining line, bar, and scatter elements to provide a comprehensive overview of treatment outcomes.

The synthesized data strongly point out that targeted therapy can offer considerable clinical advantages in malignancies of the blood by aiding to achieve better molecular reaction, increasing survival rates, and retaining tolerable intolerability levels. Such findings support the continued integration of precision-guided therapy practices within modern hematologic oncology practice.

DISCUSSION

The present study was a retrospective cohort study that focused on clinical outcomes among patients with hematologic malignancies treated with targeted treatments. The information was retrieved in electronic health records which included patient demographics, disease characteristics, treatment regimens and response rates. The main endpoints were the overall survival, progression-free survival, objective response rates, whereas the secondary endpoints were adverse event profiles and quality of life indicators. Kaplan-Meier and logistic regression statistical analyses were employed to determine the survival rates and the response rates respectively, respectively, and the statistical analysis was conducted with response rates by adjusting the results with pertinent confounding factors to obtain strong interpretations on treatment efficacy (Refae et al., 2019). The identification of actionable mutations was done using genomic profiling including whole-exome sequencing and targeted gene panels. These results were after that compared to patient responses to certain targeted agents to assess the clinical utility of precision medicine strategies (Jamalinia and Weiskirchen, 2025; Marks et al., 2017). Although these genomic findings have delivered encouraging results in determining targetable changes, there is still a problem in making these findings translate into clinical approaches applicable across the board, considering that the existing targeted therapies only target a subset of the found alterations that are deemed as druggable (Srkalović, 2019). This highlights the necessity to carry out ongoing studies on new therapeutic targets and creation of drugs that can alter therapeutically inactive carcinogenic drivers in the past (Vanamala et al., 2025). Moreover, due to the heterogeneity of tumors and the evolution of clones, continuous observation of genomic landscapes is required to adjust the treatment plan on the basis of personalized treatments by changing the approach in time and streamlining it (Ptashkin et al., 2022). In addition, the combination of multi-omics data, which includes genomics, epigenomics, transcriptomics, proteomics, and metabolomics provides a less biased approach to the disease and can give new therapeutic pathways, thus providing a solid foundation of precision medicine (Vanamala et al., 2025). The further evolution of a functional precision medicine that is based on ex vivo drug sensitivity testing can provide even more accuracy when choosing a treatment option by

evaluating the individual patient tumor response to an extensive range of therapeutic agents (Kornauth et al., 2021). The aim of this is to circumvent the issues that accompany single-omic analyses by the virtue of its comprehensive nature that unites the various forms of data. As an example, omics data can be combined to enhance the analysis and treatment of diseases (Vanamala et al., 2025). These combined methods are essential in the discovery of the intricate interactions of molecular aberrations that lead to hematologic malignancies, thus enabling the identification of synergistic drug products and biomarkers to overcome resistance (Fountzilas et al., 2022). Nonetheless, the issue is that most patients who have their genomic testing carried out on hematologic malignancy cases are not helped by precision medicine because there are no known correlations between most genetic variations and drug sensitivity (Jahrestagung Der Deutschen, Österreichische Und Schweizerme Gesellschaften Für Haeatologie Und Medizinische Oncologie, Berlin, 11). - 14. Oktober 2019: Abstracts," 2019).

CONCLUSION

In conclusion, the study reveals that target medicines are very useful in the management of blood cancer and most importantly in enhancing the progression-free survival (PFS) and the overall survival (OS) rates. The findings point to the fact that tyrosine kinase (TKIs) and monoclonal antibodies and immune checkpoint inhibitors are much more beneficial in clinical settings than traditional chemotherapy, which is more personalized and less toxic when applied in the treatment of chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), and acute myeloid leukemia (AML). Progressive free survival (PFS), which is a positive change in the reduction of the disease progression and decreased rate of side events as compared to chemotherapy also experienced significant improvements in TKI patients. Outcomes using the monoclonal antibodies in non-Hodgkin lymphoma (NHL) especially in relapsed cases were encouraging with long remission. In addition, the combination effect of immune checkpoint inhibitors and chemotherapy was observed in patients with AML, which resulted in improved treatment outcomes, which points to the possibility of overcoming treatment resistance through the application of combinatory treatment programs. The quality of life and satisfaction with treatment was a valuable data given by qualitative data based on interviewing the patient, which revealed high compliance with the therapy and a positive reaction to the particular treatment, albeit with a slight negative reaction. These results support the supposition that individualized medicine is becoming relevant in hematologic oncology. They also propagate the idea that molecular and genetic profiling can lead to the development of better and less invasive treatment using targeted medicines. The

study results suggest that further research should be carried out on the combination of particular drugs and other types of treatment. They further advise that the regimens of treatment should also be continually improved to provide the best results to the patients and the limited impact. Lastly, the findings indicate that more studies need to be conducted in the area of hematologic malignancies so as to increase the validity and effectiveness of cancer treatment.

REFERENCES

Aggregation-Induced Emission (AIE) for Cancer Diagnosis and Treatment: Mechanisms, Innovations, and Clinical Prospects. (n.d.).

Evans, W. E., Pui, C., & Yang, J. J. (2019). The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead [Review of *The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead*]. *Clinical Pharmacology & Therapeutics*, *107*(1), 176. Wiley.

Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022). Clinical trial design in the era of precision medicine [Review of *Clinical trial design in the era of precision medicine*]. *Genome Medicine*, *14*(1). BioMed Central.

Goranova-Marinova, V., Grekova, D., Георгиева, В., Andreevska, К., Gvozdeva, Y., Kassarova, M., & Грудева-Попова, Ж. (2023). Analysis of the pharmacotherapeutic effectiveness of the tyrosine kinase inhibitors therapy in patients with Chronic Myeloid Leukemia in a single hematology center in Plovdiv, Bulgaria. *Pharmacia*, *70*(4), 1355.

Hamid, G. A. (2019). Advances in Hematologic Malignancies. In *IntechOpen eBooks*. IntechOpen.

Harttrampf, A. C. (2018). Molecular Profiling in Pediatric Oncology – the MOSCATO-01 Experience // Characterization of SMARCB1-Altered Soft Tissue Sarcomas in Response to Pharmacological HDAC Inhibition. *HAL (Le Centre Pour La Communication Scientifique Directe)*.

Ikhtiar, F., Jamal, A., & Bokhari, S. M. (2025). Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies [Review of *Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies*]. *Discover Oncology*, *16*(1). Springer Nature.

Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Berlin, 11. - 14. Oktober 2019: Abstracts. (2019). *Oncology Research and Treatment*, *42*, 1.

Jamalinia, M., & Weiskirchen, R. (2025). Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment [Review of *Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment*]. *Annals of Translational Medicine*, *13*(2), 18. AME Publishing Company.

Kebede, A., Garfinkle, E. A. R., Mathew, M. T., Varga, L., Colace, S. I., Wheeler, G. S., Kelly, B., Schieffer, K. M., Miller, K. E., Mardis, E. R., Cottrell, C. E., & Potter, S. L. (2024).

Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center. *Frontiers in Oncology*, *14*.

Kinnersley, B., Sud, A., Everall, A., Cornish, A. J., Chubb, D., Culliford, R., Gruber, A., Lärkeryd, A., Mitsopoulos, C., Wedge, D. C., & Houlston, R. S. (2024). Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. *Nature Genetics*, *56*(9), 1868.

Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., Felsleitner-Hauer, V., Forte, M., Gaiger, A., Geißler, K., Greinix, H., Gstöttner, W., Hacker, M., Hartmann, B., Hauswirth, A. W., … Staber, P. B. (2021). Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. *Cancer Discovery*, *12*(2), 372.

Lica, J. J., Pradhan, B., Safi, K., Jakóbkiewicz-Banecka, J., & Hellmann, A. (2024). Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential [Review of *Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential*]. *Molecules*, *29*(17), 4280. Multidisciplinary Digital Publishing Institute.

Marks, L. J., Oberg, J. A., Pendrick, D., Sireci, A., Glasser, C. L., Coval, C., Zylber, R. J., Chung, W. K., Pang, J., Turk, A. T., Hsiao, S. J., Mansukhani, M., Bender, J. G., Kung, A. L., & Sulis, M. L. (2017). Precision Medicine in Children and Young Adults with Hematologic

Malignancies and Blood Disorders: The Columbia University Experience. *Frontiers in Pediatrics*, *5*.

Onoja, A., Otene, S. A., Onoja, A., Ibrahim, I. M., Mke, A., Okolie, I., Okoli, R., Kyoive, E., Aba, I., Orkuma, J., Nwannadi, A., & Alao, O. (2021). Prevalence and Nature of Adult Hematological Malignancies Using Bone Marrow Aspiration Cytology in a Tertiary Health Facility: A Seven Year Retrospective Review. *Western Journal of Medical and Biomedical Sciences*, *2*(1), 39.

Ortiz, M. V., Kobos, R., Walsh, M. F., Slotkin, E. K., Roberts, S. S., Berger, M. F., Hameed, M., Solit, D. B., Ladanyi, M., Shukla, N., & Kentsis, A. (2016). Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. *Pediatric Blood & Cancer*, *63*(8), 1368.

Pokorná, P., Pálová, H., Adamcová, S., Jugas, R., Tukmachi, D. A., Kýr, M., Knoflíčková, D., Koželková, K., Bystrý, V., Mejstříková, S., Merta, T., Trachtová, K., Podlipna, E., Múdrý, P., Pavelka, Z., Bajčiová, V., Tinka, P., Jarošová, M., Ivković, T. C., … Slabý, O. (2024). Real-world performance of integrative clinical genomics in pediatric precision oncology. *Laboratory Investigation*, 102161.

Ptashkin, R., Ewalt, M. D., Jayakumaran, G., Kiecka, I., Bowman, A. S., Yao, J., Casanova, J., Lin, Y.-T. D., Petrova-Drus, K., Mohanty, A., Bacares, R., Benhamida, J., Rana, S., Razumova, A., Vanderbilt, C., Remav, A. B., Rijo, I., Son-Garcia, J., Bruijn, I. de, … Arcila, M. E. (2022). Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing. *medRxiv (Cold Spring Harbor Laboratory)*.

Refae, A. A., Bayer, A., Ibrahim, E. M., Mansoor, I., Saleem, N. A., Al-Masri, O. A., AbuShakra, R. I., & Eldahna, W. M. (2019). Genomic Profiling for Patients with Solid Tumors: A Single-Institution Experience. *Annals of Clinical Oncology*, 1.

Saraceni, F., & Morè, S. (2022). Editorial: Reviews in hematologic malignancies. *Frontiers in Oncology*, *12*.

Senkevitch, E., & Durum, S. K. (2016). The promise of Janus kinase inhibitors in the treatment of hematological malignancies [Review of *The promise of Janus kinase inhibitors in the treatment of hematological malignancies*]. *Cytokine*, *98*, 33. Elsevier BV.

Sharma, I., Son, M. J., Motamedi, S., Hoeft, A., Teller, C., Hamby, T., & Ray, A. (2023). Utilization of Genomic Tumor Profiling in Pediatric Liquid Tumors: A Clinical Series. *Hematology Reports*, *15*(2), 256.

Shukla, N., Levine, M. F., Gundem, G., Domenico, D., Spitzer, B., Bouvier, N., Arango-Ossa, J. E., Głodzik, D., Medina-Martínez, J. S., Bhanot, U., Gutiérrez-Abril, J., Zhou, Y., Fiala, E., Stockfisch, E., Li, S., Rodriguez-Sanchez, I., O'Donohue, T. J., Cobbs, C. C., Roehrl, M. H. A., … Papaemmanuil, E. (2022). Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. *Nature Communications*, *13*(1).

Shukry, S., Hariri, F., & Al-Nehmi, A. W. (2019). Target Therapy in Hematological Malignancies. In *IntechOpen eBooks*. IntechOpen.

Simon, J., Reita, D., Guérin, É., Lhermitte, B., Weingertner, N., Lefèbvre, F., Karanian, M., Masliah-Planchon, J., Lindner, V., Onéa, A., Jannier, S., Salmon, A., Bergthold, G., Vincent, F., Deschuyter, M., Barbaza, M., & Entz-Werlé, N. (2024). Clinical impact of large genomic explorations at diagnosis in 198 pediatric solid tumors: a monocentric study aiming practical feasibility of precision oncology. *BMC Cancer*, *24*(1).

Sochacka-Ćwikła, A., Mączyński, M., & Regiec, A. (2021). FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review [Review of *FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review*]. *Cancers*, *14*(1), 87. Multidisciplinary Digital Publishing Institute.

Srkalović, G. (2019). Genomics in Hematology and Oncology Practice. *Acta Medica Academica*, *48*(1), 1.

Trinder, S., Ziegler, D. S., & Lau, L. M. S. (2025). From Sequencing to Survival: The Growing Role of Precision Medicine in Paediatric Oncology. *Targeted Oncology*.

Vanamala, J., Sivaramakrishnan, V., & Mummidi, S. (2024). Editorial: Integrated multi-omic studies of metabolic syndrome, diabetes and insulin-related disorders: mechanisms, biomarkers, and therapeutic targets. Frontiers in Endocrinology, 15, 1537554.